Talpaz, Moshe <br/><br/>
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2005 
 - 6247-55 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-05-0882  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cytarabine--administration & dosage<br/>Drug Administration Schedule<br/>Drug Carriers<br/>Drug Combinations<br/>Female<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Polyethylene Glycols--administration & dosage<br/>Recombinant Proteins